x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Proactive - Interviews for investors

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

business investing

All Episodes

00:04:46

NanoViricides advances antiviral drug with Phase II...

Proactive - Interviews for investors ·

2025/01/28

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive shared pivotal updates with Proactive, announcing the company’s engagement of a Clinical Research Organization to conduct a Phase II clinical trial for its innovative broad-spectrum antiviral therapy. This milestone represents a significant step in advancing the therapy through the regulatory process. The upcoming Phase II trial will evaluate the effectiveness of the therapy in treating MPox, a disease caused by the human Mpox

en

00:04:41

Critical Minerals: M2i Global CEO talks supply chain...

Proactive - Interviews for investors ·

2025/01/28

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to discuss the company’s response to the Executive Order "Unleashing American Energy," signed by U.S. President Donald Trump on January 20, 2025. The order aligns closely with M2i’s mission to enhance domestic critical mineral production, supporting U.S. defense sector resilience and economic growth. Rosende highlighted that the Executive Order accelerates M2i’s ability to expand Joint Venture arrangements and critical mineral

en

00:05:27

Livium CEO on recycling refocus and expansion plans

Proactive - Interviews for investors ·

2025/01/28

Livium Ltd (ASX:LIT, OTC:LMMFF) managing director and CEO Simon Linge talks with Proactive’s Tylah Tully about the company’s latest updates, focusing on its strategic initiatives and near-term goals. Linge highlighted Livium’s strong emphasis on scaling its battery recycling business to meet the growing influx of large-format lithium-ion batteries, positioning the company as a key player in this growing sector. He discussed two other patented technologies, including LieNA® technology, developed in

en

00:01:36

Just the Facts: Leeuwin Metals secures A$3.25 million...

Proactive - Interviews for investors ·

2025/01/28

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Leeuwin Metals Ltd (ASX: LM1). Leeuwin Metals has raised A$3.25 million through a two-tranche share placement priced at A$0.098 per share, reflecting an 18.3% discount to the last closing price. The placement attracted strong interest from institutional and sophisticated investors, with contributions of approximately A$250,000 from directors and management, subject to shareholder approval. The placement comprises two

en

00:06:25

Sona Nanotech's cancer treatment study published in...

Proactive - Interviews for investors ·

2025/01/27

Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share the publication of groundbreaking findings from the company’s pre-clinical breast cancer and melanoma efficacy studies in the prestigious scientific journal Frontiers in Immunology. This comprehensive research highlights the transformative potential of Sona’s Targeted Hyperthermia Therapy (THT) and includes critical new follow-up data on its immune-activating properties. Sona’s proprietary technology employs patented,

en

00:07:23

AOTI’s Dr Mike Griffiths on breakthrough for diabetic...

Proactive - Interviews for investors ·

2025/01/27

AOTI Inc (AIM:AOTI) CEO, president, and co-founder Dr Mike Griffiths talked with Proactive about the company’s efforts to revolutionise chronic wound care. AOTI is focused on treating conditions like diabetic foot ulcers with its unique home-based oxygen therapy, designed to promote durable healing. Griffiths highlighted the staggering $80 billion US diabetic foot ulcer care market and shared that AOTI is well-positioned to expand within this space. He noted that AOTI’s strong clinical evidence and

en

00:06:01

hVIVO partners with ILiAD Biotechnologies for pivotal...

Proactive - Interviews for investors ·

2025/01/27

hVIVO PLC CEO Yamin 'Mo' Khan talked with Proactive's Stephen Gunnion about the company's involvement in a world-first Phase 3 human challenge trial for a pertussis (whooping cough) vaccine candidate. The trial, in partnership with ILiAD Biotechnologies, is expected to start in the second half of this year. Khan highlighted the importance of this milestone for hVIVO, noting that it will be the company's largest challenge trial to date and its first bacterial challenge trial. The trial data aims to

en

00:07:56

Fineqia International CEO unveils first DeFi yield ETP

Proactive - Interviews for investors ·

2025/01/27

Fineqia International Inc CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued

en

00:04:31

GoviEx Uranium unveils low-risk, high-reward Muntanga...

Proactive - Interviews for investors ·

2025/01/24

GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) CEO Daniel Major discussed the just-released feasibility study for the Mutanga Uranium project in Zambia with Proactive's Stephen Gunnion. Major highlighted that the study outlines solid project economics, including a net present value (NPV) of $243.00 million and an internal rate of return (IRR) of 20.8% at a uranium price of $90.00 per pound. He described Mutanga as a straightforward open-pit project benefiting from local infrastructure and low technical

en

00:11:25

ANGLE PLC says Nature Medicine journal highlights...

Proactive - Interviews for investors ·

2025/01/24

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking research using the Parsortix system. This system has enabled significant advancements in cancer research, including a recent study published in Nature Medicine that explores stopping the metastatic spread of cancer.Newland explained how Parsortix helps identify and analyse circulating tumour cell clusters, which are critical to cancer progression. He highlighted research led by

en

00:05:31

Iofina CEO on record iodine production in 2024,...

Proactive - Interviews for investors ·

2025/01/24

Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker talked with Proactive's Stephen Gunnion about the company's record achievements in 2024 and its ambitious growth plans for 2025. Becker detailed the production of over 630 metric tons of iodine last year, including a 13% year-over-year increase. He highlighted that the new IO#10 plant, which reached full capacity in late 2024, will contribute significantly to this year's output. The company is also making strides with IO#11, set to begin production

en

00:06:32

Lisata Therapeutics CEO David Mazzo on ASCEND and...

Proactive - Interviews for investors ·

2025/01/24

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive's Stephen Gunnion with an update on the company's pancreatic cancer trials. The company recently announced preliminary results from its ASCEND phase 2 trial at the ASCO Gastrointestinal Conference. According to Mazzo, data from the randomized, double-blind, placebo-controlled Cohort A group demonstrated promising trends in overall survival and efficacy. He highlighted that four complete responses were observed in the Certepetide

en

00:12:35

ImmuPharma CEO Tim McCarthy shares latest...

Proactive - Interviews for investors ·

2025/01/24

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s recent groundbreaking developments in autoimmune disease treatment. He highlighted the progress made with their P140 platform, emphasising its potential to address multiple autoimmune diseases and transform patient care. McCarthy explained, “This is a breakthrough in a lot of different ways,” referencing recent preclinical findings that allow the identification and categorisation of

en

00:04:24

Giyani Metals announces 'transformative' SEZ licence...

Proactive - Interviews for investors ·

2025/01/24

Giyani Metals Corp (TSX-V:EMM, OTC:CATPF) CEO Charles FitzRoy joined Proactive's Stephen Gunnion with news that the company has secured a 50-year Special Economic Zone (SEZ) Investor License for its battery-grade manganese (HPMSM) commercial plant site to be built in Botswana. The award of the SEZ License designates Giyani’s Commercial Plant as a Single Factory Special Economic Zone. The Commercial Plant will be located adjacent to its K.Hill manganese mine site, near Kanye, Botswana. FitzRoy

en

00:05:00

Helix Exploration raises £5mln in placing as it...

Proactive - Interviews for investors ·

2025/01/24

HeLIX Exploration PLC (AIM:HEX) chairman David Minchin joined Proactive's Stephen Gunnion with news that the company has upgraded its helium reserves and economic estimates for the Rudyard Project, in Montanta, and raised around £5 million through an equity issuance. The proceeds are earmarked to support spending on a gas processing plant and to progress the Rudyard and Ingomar Dome projects. Minchin said the decision to move forward with an equity raise comes after a detailed review of the

en

00:04:21

Ariana Resources MD on beating production guidance...

Proactive - Interviews for investors ·

2025/01/24

Ariana Resources PLC (AIM:AAU) managing director Kerim Sener talked with Proactive's Stephen Gunnion about the company’s production results and ongoing projects. Ariana has exceeded production guidance for the eighth consecutive year at its Zenit mining operation in Turkey, delivering nearly 21,000 ounces of gold in 2024. Sener emphasised that the Kiziltepe processing plant continues to perform well despite its age, aided by additional ore from the Tavsan operation. The company reported gross

en

00:06:26

Greatland Gold CEO on impressive debut for Telfer mine

Proactive - Interviews for investors ·

2025/01/24

Greatland Gold PLC (AIM:GGP, OTC:GRLGF) CEO Shaun Day talked with Proactive's Stephen Gunnion about the company's strong production numbers for December following the completion of the Telfer and Havieron acquisition, consolidating ownership under Greatland. The company delivered 33,000 ounces of gold equivalent in just 27 days. Day emphasised the robust financial position of Greatland, with $145 million in cash and an undrawn debt facility of $75 million, providing over $220 million in liquidity

en

00:04:19

Oncology outlook: ASX small caps driving innovation...

Proactive - Interviews for investors ·

2025/01/24

The global oncology drug market, valued at USD 231.56 billion in 2024, is expected to grow to USD 532.91 billion by 2031, driven by demand for targeted therapies, biomarker-based treatments, and immunotherapies. Several ASX-listed companies are contributing to this innovation: Arovella Therapeutics Ltd: Developing its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours. Lead product ALA-101 uses CAR19-iNKT cells to target the CD19 antigen. The company

en

00:01:27

Just the Facts: Silver Mines launches 3,000-metre...

Proactive - Interviews for investors ·

2025/01/24

Proactive’s Tylah Tully breaks down ‘Just the facts’ of the latest news from Silver Mines Ltd (ASX:SVL). The company has announced the commencement of drilling at its Elsienora Project, part of the Tuena Gold Project in New South Wales. Located 80 kilometres south of Orange, the project includes multiple gold and silver prospects. Historical exploration highlights include: 29 metres @ 1.53 g/t gold from surface, 8 metres @ 3.14 g/t gold from 30 metres, and 21 metres @ 0.89 g/t gold from 207

en

00:01:32

Just the Facts: Maximus expands resource potential...

Proactive - Interviews for investors ·

2025/01/24

Proactive’s Tylah Tully breaks down ‘Just the facts’ of the latest news from Maximus Resources Ltd (ASX:MXR, OTC:MXRRF). Maximus has identified shallow high-grade gold mineralisation at the Eagles Nest deposit, 7 kilometres south of the Wattle Dam Gold Project in Western Australia’s Eastern Goldfields. Recent reverse circulation (RC) drilling produced significant results, including: 10 metres @ 2.24 g/t gold from 37 metres, including 2 metres @ 2.71 g/t and 3 metres @ 3.88 g/t. Additional scout

en

4,685 results

Similar Podcasts

Bloomberg Talks

Bloomberg

Minute Briefing

The Wall Street Journal

Fintech Insider Podcast by 11:FS

11:FS

Midday News

Multimedia Ghana

Best of Business

Newstalk ZB